No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
www.luye.cnNo one on the platform currently holds 2186.HK.
No tracked institution reports a position in 2186.HK as of their last filing.
No one on the platform has traded 2186.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.3% | — | — | — | ||
| Rev. Growth % | 4.1% | 2.6% | ||||
| Profit Margin % | 9.8% | 6.8% | 15.1% | |||
| Free Cash Flow Margin % | 12.4% | -4.8% | -6.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.5B | -2.5% | $0.18 | $0.18–$0.19 | — | 2 |
| 2027 | $6.8B | +5.4% | $0.19 | $0.16–$0.22 | — | 2 |
| 2028 | $7.4B | +8.8% | $0.24 | $0.22–$0.26 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-30 | $0.06 | $0.03 | -48.8% |
| 2026-03-29 | $0.09 | $0.09 | +0.0% |
| 2025-08-28 | $0.08 | $0.09 | +18.9% |
| 2025-03-30 | $0.12 | $0.02 | -79.7% |
| 2024-03-28 | $0.11 | $0.11 | +2.4% |
| 2023-08-30 | $0.03 | $0.04 | +35.4% |
| 2023-03-30 | $0.07 | $0.10 | +48.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2186.HKLuye Pharma Group Ltd. | $1.79 | +0.28% | $7.2B | — |
| 0570.HKChina Traditional Chinese Medicine Holdings Co. Limited | $1.27 | +1.19% | $6.4B | — |
| 0719.HKShandong Xinhua Pharmaceutical Company Limited | $5.42 | -1.36% | $8.2B | — |
| 1681.HKConsun Pharmaceutical Group Limited | $13.26 | -0.15% | $11.1B | — |
| 1858.HKBeijing Chunlizhengda Medical Instruments Co., Ltd. |
| $7.72 |
| -1.47% |
| $4.6B |
| — |
| 2142.HKHBM Holdings Limited | $12.73 | -4.86% | $10.7B | — |
| 2315.HKBiocytogen Pharmaceuticals (Beijing) Co., Ltd. | $57.00 | -4.12% | $23.1B | — |
Source: Financial Modeling Prep · peers by sector/industry